Preliminary Study on Type I Interferon as a Mucosal Adjuvant for Human Respiratory Syncytial Virus F Protein

Preliminary Study on Type I Interferon as a Mucosal Adjuvant for Human Respiratory Syncytial Virus F Protein

<b>Background: </b>Human respiratory syncytial virus (HRSV) imposes a significant disease burden on infants and the elderly. Intranasal immunization using attenuated live vaccines and certain vector vaccines against HRSV has completed phase II clinical trials with good safety and efficac...

Full description

Saved in:

Bibliographic Details
Main Authors:	Hongqiao Hu, Li Zhang, Lei Cao, Jie Jiang, Yuqing Shi, Hong Guo, Yang Wang, Hai Li, Yan Zhang
Format:	Article
Language:	English
Published:	MDPI AG 2024-11-01
Series:	Vaccines
Subjects:	human respiratory syncytial virus type I interferon mucosal adjuvant protective effects
Online Access:	https://www.mdpi.com/2076-393X/12/11/1297
Tags:	Add Tag No Tags, Be the first to tag this record!

Similar Items

Cost-effectiveness of bivalent respiratory syncytial virus prefusion F vaccine for prevention of respiratory syncytial virus among older adults in Germany
by: Ahuva Averin, et al.
Published: (2025-12-01)

Cost-Effectiveness of Bivalent Respiratory Syncytial Virus Prefusion F Vaccine for Prevention of Respiratory Syncytial Virus Among Older Adults in Greece
by: George Gourzoulidis, et al.
Published: (2024-10-01)

The Impact of Palivizumab for Respiratory Syncytial Virus Prophylaxis on Preschool Childhood Asthma
by: Hannah Ora Hasson, et al.
Published: (2024-11-01)

Immune Responses to Respiratory Syncytial Virus Vaccines: Advances and Challenges
by: Gabriela Souza da Silva, et al.
Published: (2024-11-01)

Recommendation for the use of respiratory syncytial virus vaccines
by: Ping-Ing Lee, et al.
Published: (2025-02-01)

Cost-effectiveness analysis of respiratory syncytial virus vaccination with the adjuvanted prefusion F protein vaccine (RSVPreF3 OA) for adults ≥60 years old in Japan
by: Akiko Mizukami, et al.
Published: (2024-12-01)

Respiratory Syncytial Virus: What is the Risk Over 60?
by: Oğuzhan Acet, et al.
Published: (2024-12-01)

Role of bovine respiratory syncytial virus in etiology of respiratory diseases on milk farms
by: S. V. Koteneva, et al.
Published: (2021-03-01)

RSV Vaccine with Nanoparticle-Based Poly-Sorbitol Transporter (PST) Adjuvant Improves Respiratory Protection Against RSV Through Inducing Both Systemic and Mucosal Humoral Immunity
by: Seong-Mook Jung, et al.
Published: (2024-11-01)

Characteristics of the First Italian Older Adults Vaccinated with an Adjuvanted Respiratory Syncytial Virus (RSV) Vaccine
by: Alexander Domnich, et al.
Published: (2025-01-01)

Circulation of Respiratory Syncytial Virus (RSV) in Poland Between Seasons of 2009/2010 and 2022/2023 Based on SENTINEL System
by: Karol Szymański, et al.
Published: (2025-01-01)

Epidemiology and clinical characteristics of hospitalized adults with respiratory syncytial virus infection at a medical center in northern Taiwan
by: Wen-Cheng Chang, et al.
Published: (2024-12-01)

Prevalence of Respiratory Syncytial Virus Infection in Hospitalized COPD Patients in Spain Between 2018–2022
by: Rosa María Gómez-García, et al.
Published: (2025-01-01)

Impact of Respiratory Syncytial Virus (RSV) in Adults 60 Years and Older in Spain
by: Sara Jimeno Ruiz, et al.
Published: (2024-11-01)

Respiratory syncytial virus vaccination among US adults aged ≥60 years
by: Xiaozhen Geng, et al.
Published: (2024-12-01)

Prevention of respiratory syncytial virus infection in children. Recommendations of the Polish Society of Paediatrics and the National Paediatric Consultant
by: Teresa Jackowska, et al.
Published: (2024-12-01)

Comparative study on the epidemiological characteristics and hazards of respiratory syncytial virus and influenza virus infections among elderly people
by: Jiangtao Yu, et al.
Published: (2024-10-01)

Progress and challenges in the clinical evaluation of immune responses to respiratory mucosal vaccines
by: Xuanxuan Zhang, et al.
Published: (2024-12-01)

Adjuvant and neoadjuvant immunotherapy for acral and mucosal melanoma
by: Takaya Komori, et al.
Published: (2025-01-01)

Foreword: Prevention of COVID-19, Influenza, and Respiratory Syncytial Virus in At-Risk Populations
by: Stefan Gravenstein
Published: (2024-12-01)

Bivalirudin exerts antiviral activity against respiratory syncytial virus-induced lung infections in neonatal mice
by: Zhuang Shihao, et al.
Published: (2022-09-01)

Understanding the local-level variations in seasonality of human respiratory syncytial virus infection: a systematic analysis
by: Sheng Ye, et al.
Published: (2025-01-01)

Fumarprotocetraric acid and geraniin were identified as novel inhibitors of human respiratory syncytial virus infection in vitro
by: Chao Wang, et al.
Published: (2024-12-01)

Economic and clinical burden associated with respiratory syncytial virus and impact of universal immunization with nirsevimab in Italy
by: Andrea Marcellusi, et al.
Published: (2025-01-01)

Respiratory Syncytial Virus and Other Respiratory Viruses in Hospitalized Infants During the 2023–2024 Winter Season in Mexico
by: José J. Leija-Martínez, et al.
Published: (2024-12-01)

The Development of Animal Models for Respiratory Syncytial Virus (RSV) Infection and Enhanced RSV Disease
by: Gengxin Zhang, et al.
Published: (2024-10-01)

Evaluation of mucosal adjuvants to chitosan-nanoparticle-based oral subunit vaccine for controlling salmonellosis in broilers
by: Raksha Suresh, et al.
Published: (2025-02-01)

News Media Reports of Respiratory Syncytial Virus in Canada and the United States During the 2022–2023 Respiratory Virus Season: A Cross‐Sectional Study
by: Sherilyn K. D. Houle, et al.
Published: (2024-11-01)

Clinical manifestations, para-clinical features and outcome of Iranian adults with respiratory syncytial virus (RSV) infection: a report from hospitalized patients
by: Maryam Shafaati, et al.
Published: (2025-02-01)

Adjuvant system AS01: from mode of action to effective vaccines
by: François Roman, et al.
Published: (2024-12-01)

Optimization of cultivation parameters for bovine respiratory syncytial virus strain Vologda/2019
by: V. V. Kirpichenko, et al.
Published: (2020-09-01)

The established of a machine learning model for predicting the efficacy of adjuvant interferon alpha1b in patients with advanced melanoma
by: Linhan Jiang, et al.
Published: (2024-11-01)

CULTURAL PROPERTIES OF BOVINE RESPIRATORY SYNCYTIAL VIRUS STRAIN AB1908
by: V. V. Kirpichenko, et al.
Published: (2019-12-01)

Circulation and Codetections of Influenza Virus, SARS-CoV-2, Respiratory Syncytial Virus, Rhinovirus, Adenovirus, Bocavirus, and Other Respiratory Viruses During 2022–2023 Season in Latvia
by: Inara Kampenusa, et al.
Published: (2024-10-01)

Mild encephalitis/encephalopathy with reversible splenial lesion (MERS) associated with respiratory syncytial virus and Pseudomonas putida infection: A case report
by: Yanxiang Chen, et al.
Published: (2024-10-01)

Burden of Respiratory Syncytial Virus Infection in Children and Older Patients Hospitalized with Asthma: A Seven-Year Longitudinal Population-Based Study in Spain
by: Rosa María Gomez-Garcia, et al.
Published: (2024-11-01)

Prospective hospital-based cohort studies of Respiratory Syncytial Virus (RSV) infections in infants under one year during and after the SARS-CoV-2 pandemic in Japan
by: Koo Nagasawa, et al.
Published: (2024-12-01)

Economic and Clinical Benefits of Bivalent Respiratory Syncytial Virus Prefusion F (RSVpreF) Maternal Vaccine for Prevention of RSV in Infants: A Cost-Effectiveness Analysis for Mexico
by: José Luis Huerta, et al.
Published: (2025-01-01)

Interaction Between the Matrix Protein and the Polymerase Complex of Respiratory Syncytial Virus
by: Elliot B. Atchison, et al.
Published: (2024-12-01)

Respiratory syncytial virus burden in children under 2 years old in understudied areas worldwide: gap analysis of available evidence, 2012–2022
by: Rodrigo Sini de Almeida, et al.
Published: (2024-11-01)